Investigational Drug Development

Looking Forward

Fujifilm is conducting research to study the potential of new drugs to address unmet medical needs, focusing on cancer, infectious diseases and central nervous system diseases.

Fujifilm currently has clinical trials in the United States for influenza, cancer, Alzheimer’s disease and COVID-19. These clinical trials are underway in collaboration with various institutions throughout the country.

In 2016, Fujifilm provided the anti-influenza drug favipiravir (T-705) to the Guinean Government, as one of the supplies procured by the Japanese government’s emergency grant aid to counter the outbreak of Ebola Virus disease.

*Avigan Tablet has not been approved by the FDA for use in the USA

Investigational drug pipeline

Infectious diseases

Code	Mode of Action	Indication	Region	Stage	Clinical Trial Information
T-705	RNA polymerase inhibitor	Influenza	Japan	Approved	https://clinicaltrials.gov/ct2/results?cond=&term=T-705&cntry=&state=&city=&dist=
		Influenza	U.S.A.	Phase 3
		Severe fever with thrombocytopenia syndrome	Japan	Phase 3
		Coronavirus disease 2019 (COVID-19)	Japan	IND filing
		Coronavirus disease 2019 (COVID-19)	U.S.A.	Phase 2
T-3811	Bacterial DNA gyrase inhibitor, topoisomerase V inhibitor	Respiratory and urinary tract infection	China	IND filing
T-4288	Bacterial protein synthesis inhibitor	Otorhinolaryngologic infections	Japan	IND filing
T-4288	Bacterial protein synthesis inhibitor	Respiratory tract infections	Japan	NDA filing

Oncology

Code	Mode of Action	Indication	Region	Stage	Clinical Trial Information
FF-10502-01	DNA polymerase inhibitor	Advanced solid tumors	U.S.A.	Phase 2	https://clinicaltrials.gov/ct2/results?cond=&term=FF-10502-01&cntry=&state=&city=&dist=
FF-21101	Anti P-cadherin antibody, ⁹⁰Y conjugate	Advanced solid tumors	Japan	Phase 1	https://clinicaltrials.gov/ct2/results?cond=&term=FF-21101&cntry=&state=&city=&dist=
FF-21101	Anti P-cadherin antibody, ⁹⁰Y conjugate	Advanced solid tumors	U.S.A.¹	Phase 2
FF-1311	PSMA-targeted imaging agent, ^99mTc labeled	Prostate cancer	Japan	Phase 2
F-1515	Somatostatin receptor targeted agent, ¹⁷⁷Lu labeled	Neuroendocrine tumors	Japan	IND filing
F-1614	Adrenergic neuron-blocking agent, ¹³¹I labeled	Pheochromocytoma and paraganglioma	Japan	IND filing
FF-10101-01	FLT3 inhibitor	Acute myeloid leukemia	U.S.A.	Phase 1	https://clinicaltrials.gov/ct2/results?cond=&term=FF-10101-01&cntry=&state=&city=&dist=
FF-10832	Liposomal gemcitabine (DNA replication polymerase inhibitor)	Advanced solid tumors	U.S.A.	Phase 2	https://clinicaltrials.gov/ct2/results?cond=&term=FF-10832&cntry=&state=&city=&dist=
FF-10850	Liposomal topotecan (topoisomerase I inhibitor)	Advanced solid tumors	U.S.A.	Phase 1	https://clinicaltrials.gov/ct2/results?cond=&term=FF-10850&cntry=&state=&city=&dist=

¹Phase 1 expansion study

Neurology

Code	Mode of Action	Indication	Region	Stage	Clinical Trial Information
T-817MA	Neuroprotectant, microglial modulator, neuroplasticity facilitator	Alzheimer’s disease	Japan	Phase 2	https://clinicaltrials.gov/ct2/results?cond=&term=T-817MA&cntry=&state=&city=&dist=

Others

Code	Mode of Action	Indication	Region	Stage	Clinical Trial Information
FF-10501-01	IMPDH inhibitor	Myelodysplastic syndromes	Japan	Phase 1	https://clinicaltrials.gov/ct2/results?cond=&term=FF-10501-01&cntry=&state=&city=&dist=

The drug candidates created or tested by direct or indirect affiliates of FUJIFILM Holdings Corporation that are referred to on this page are still at development stage and not yet approved for commercialization. A future use and commercialization will be subject to the prior granting of a marketing authorization in the given territory and compliance with applicable laws.

Expanded access/Compassionate use

Currently, FUJIFILM Pharmaceuticals U.S.A., Inc. is not accepting expanded access/compassionate use requests.

Partnership Strategy

We are seeking the following partners:

Companies interested in clinical development and commercialization of Fujifilm’s pipeline drugs.
Companies willing to provide immune checkpoint inhibitors for, and/or co-sponsor clinical development of, combination therapies with Fujifilm liposomal drugs (FF-10832 and FF-10850).